Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database

Introduction Subjects with autosomal dominant polycystic kidney disease (ADPKD) who were taking tolvaptan experienced aminotransferase elevations more frequently than those on placebo in the TEMPO 3:4 (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and it...

Full description

Saved in:

Bibliographic Details
Published in:	Drug safety Vol. 38; no. 11; pp. 1103 - 1113
Main Authors:	Watkins, Paul B., Lewis, James H., Kaplowitz, Neil, Alpers, David H., Blais, Jaime D., Smotzer, Dan M., Krasa, Holly, Ouyang, John, Torres, Vicente E., Czerwiec, Frank S., Zimmer, Christopher A.
Format:	Journal Article
Language:	English
Published:	Cham Springer International Publishing 01.11.2015 Springer Nature B.V
Subjects:	Adult Antidiuretic Hormone Receptor Antagonists - adverse effects Benzazepines - adverse effects Chemical and Drug Induced Liver Injury - diagnosis Chemical and Drug Induced Liver Injury - epidemiology Clinical trials Conflicts of interest Cysts Databases, Factual - statistics & numerical data Drug dosages Drug Safety and Pharmacovigilance Female Heart failure Humans Kidney diseases Liver Male Medicine Medicine & Public Health Middle Aged Original Original Research Article Pharmaceutical industry Pharmacology/Toxicology Polycystic Kidney, Autosomal Dominant - diagnosis Polycystic Kidney, Autosomal Dominant - epidemiology Randomized Controlled Trials as Topic - methods Randomized Controlled Trials as Topic - statistics & numerical data Retrospective Studies Statistics as Topic - methods Liver Injury Tolvaptan Autosomal Dominant Polycystic Kidney Disease Hepatic Cyst Hepatocellular Injury
ISSN:	0114-5916, 1179-1942
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!